Viridian Therapeutics’ Veligrotug Achieves Positive Topline Results in Phase 3 THRIVE Clinical Trial for Thyroid Eye Disease

Clinical Trial Success:
Veligrotug (VRDN-001) achieved all primary and secondary endpoints in the THRIVE phase 3 clinical trial for thyroid eye disease (TED), demonstrating robust clinical activity and safety.

Efficacy:
The trial showed a 70% proptosis responder rate and a 2.9 mm mean reduction in proptosis from baseline, with 54% of patients achieving complete resolution of diplopia.

Safety Profile:
Veligrotug was generally well-tolerated, with no treatment-related serious adverse events (SAEs) and a low rate of hearing impairment (16% vs. 10.5% in the placebo group).

Future Plans:
Viridian Therapeutics plans to submit a biologics license application (BLA) for veligrotug in the second half of 2025 and has initiated two global phase 3 trials (REVEAL-1 and REVEAL-2) for VRDN-003, a subcutaneous, half-life-extended anti-IGF-1R antibody.

Competitive Landscape:
The success of veligrotug positions it as a potential competitor to Amgen's Tepezza (teprotumumab) in the treatment of thyroid eye disease.